NewEdge Advisors LLC Sells 11,016 Shares of Becton, Dickinson and Company $BDX

NewEdge Advisors LLC trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 25.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,016 shares of the medical instruments supplier's stock after selling 11,016 shares during the quarter. NewEdge Advisors LLC's holdings in Becton, Dickinson and Company were worth $4,996,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of BDX. California State Teachers Retirement System increased its stake in shares of Becton, Dickinson and Company by 14,668.6% during the second quarter. California State Teachers Retirement System now owns 69,907,953 shares of the medical instruments supplier's stock worth $10,579,171,000 after buying an additional 69,434,598 shares during the period. Auto Owners Insurance Co raised its position in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock worth $790,079,000 after acquiring an additional 40,528,680 shares in the last quarter. BlackRock Inc. acquired a new position in Becton, Dickinson and Company in the second quarter valued at $3,721,533,000. Norges Bank purchased a new position in Becton, Dickinson and Company during the 4th quarter worth approximately $734,321,000. Finally, Bank of America Corp DE acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $474,993,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This represents a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,005 shares of company stock valued at $1,423,580 in the last 90 days. Insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $183.21 on Tuesday. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The firm has a 50-day moving average of $173.06 and a two-hundred day moving average of $160.49. The firm has a market capitalization of $50.48 billion, a PE ratio of 55.18, a P/E/G ratio of 12.53 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the business earned $3.68 earnings per share. The firm's revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is presently 126.51%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on BDX. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Jefferies Financial Group reiterated a "buy" rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Piper Sandler increased their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Friday, August 7th. Royal Bank Of Canada raised their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research note on Thursday, August 13th. Finally, Evercore set a $180.00 price target on Becton, Dickinson and Company in a research report on Monday, July 6th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $187.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.